Literature DB >> 3492701

Differences in drug susceptibility between isolates of Pseudomonas cepacia recovered from patients with cystic fibrosis and other sources and its relationship to beta-lactamase focusing pattern.

S C Aronoff, P H Labrozzi.   

Abstract

Pseudomonas cepacia, a significant pulmonary pathogen among children with cystic fibrosis (CF), often possesses an inducible beta-lactamase. The beta-lactamase isoelectric focusing pattern and beta-lactam susceptibility of CF and non-CF isolates of P. cepacia were compared. Against all of the test strains, ceftazidime and piperacillin were more effective than aztreonam. More CF isolates were resistant to 8 micrograms/ml of ceftazidime than non-CF isolates. Isoelectric focusing of cefoxitin-induced, cell-free preparations of the CF isolates produced significantly more bands than comparable preparations of non-CF isolates. Organisms producing a beta-lactamase band that focused in the pH range of 8.5 to 8.7 were significantly more resistant to 8 micrograms/ml of ceftazidime than other isolates. The increased resistance of CF isolates of P. cepacia to ceftazidime may be the result of the production of a specific bacterial beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3492701     DOI: 10.1002/ppul.1950020609

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  3 in total

1.  Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein.

Authors:  J L Burns; D K Clark
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates.

Authors:  S C Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

3.  Subgrouping of Pseudomonas cepacia by cellular fatty acid composition.

Authors:  G M Mukwaya; D F Welch
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.